These include mitochondrial complex I inhibitors34 and chromatin helicase DNA-binding factor CHD1 in PTEN-inactive prostate cancer cells35, polynucleotide kinase/phosphatase (PNKP) in PTEN-deficient lung and colon cancer cells, and NUAK family kinase 1 (NUAK1) in PTEN-deficient breast cancer cells36. This evidence concerns the gene PTEN and breast cancer.